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Background  
Calcium and magnesium determine water hardness and react with soap to form scum.  
Hard water, with or without soap scum, was expected to exacerbate dermatitis affecting 
daily life. In Chiba prefecture, Japan, where our university hospital is located, the 
hardness of home tap water is approximately 92 mg/L, the second highest level in 
Japan.   
Objective 
Hard water may affect the symptoms of atopic dermatitis (AD). Therefore, we sought to 
examine the effect of water hardness on AD in Chiba prefecture. 
Methods 
For this objective, we used ultra-pure soft water (UPSW), in which both mineral 
components have been almost completely removed, to evaluate clinical and objective 
improvements in skin barrier function in children with AD via a randomized, 
double-blind, placebo-controlled, crossover pilot study. We placed a machine in the 
bathroom of each home, and the child AD patients received shower treatment with 
UPSW or ordinary tap water (placebo) for 6 weeks. After a 2-week washout period, the 
treatments were switched between patient groups. Over the course of the study, the 
water hardness was monitored. We evaluated multiple independent primary outcomes. 
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Clinical symptoms were assessed by the eczema area and severity index (EASI) score. 
We measured out-in skin transparency (OIST) using a yellow dye and transepidermal 
water loss (TEWL). The patients’ evaluations of pruritus and satisfaction with therapy 
were both evaluated using the visual analogue scale (VAS). We also measured serum 
LDH, TARC, and eosinophil blood counts in addition to bacterial skin cultures specific 
for Staphylococcus aureus. 
Results 
Eleven AD patients completed the entire study course. Although there were no 
significant differences in EASI (P = 0.21) or TEWL (P = 0.14 and 0.79), statistically 
significant differences were detected in OIST (P = 0.048), and VAS scores for pruritus 
(P = 0.044) and satisfaction with therapy (P = 0.022). We were not able to detect 
significant differences in LDH or TARC blood levels or in eosinophil counts between 
UPSW-allocated and tap water-allocated patients. We also failed to show a significant 
difference in the bacterial cultures of Staphylococcus aureus on the skin.  
Conclusion 
Shower treatment with UPSW is supposedly beneficial in AD patients in terms of OIST 
and VAS scores for pruritus and satisfaction with therapy. 
Abbreviations: atopic dermatitis (AD), calcium (Ca
2+
), magnesium (Mg
2+
), out-in skin 
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transparency (OIST), the eczema area and severity index (EASI), transepidermal water 
loss (TEWL), ultra-pure soft water (UPSW), visual analogue scale (VAS) 
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1. Introduction 
 Calcium (Ca
2+
) and magnesium (Mg
2+
) present in water determine water hardness. 
Water hardness is most commonly expressed in milligrams of calcium carbonate 
equivalent per liter. Water containing Ca
2+
 concentrations below 60 mg/L is generally 
considered soft, 60–120 mg/L as moderately hard, 120–180 mg/L as hard, and more 
than 180 mg/L as very hard [1]. 
Exposure to hard water was reported to be a risk factor for atopic dermatitis (AD) in a 
cohort study of primary school children in Nottinghamshire, UK (where the water 
hardness is 118–314 mg/L) [2] and also in Osaka, Japan (water hardness of 35.2–100 
mg/L) [3]. Ca
2+
 and Mg
2+
 react with soap to form an insoluble precipitate known as 
“soap scum”. Since invisible soap scum binds tightly to the skin surface and cannot be 
rinsed away easily, it might exacerbate AD. In Chiba, where our university hospital is 
located, the Ca
2+
 concentration in home tap water is approximately 92 mg/L, the second 
highest level in Japan. 
 To evaluate clinical and objective improvements in skin barrier functions by 
shower treatment using water devoid of these two mineral components, we used 
ultra-pure soft water (UPSW), in which Ca
2+
 and Mg
2+
 have been almost completely 
replaced by sodium ions using a cation-exchange resin, and performed a randomized, 
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double-blind, placebo-controlled, crossover pilot study. In addition to assessment of the 
eczema area and severity index (EASI) score [4], we used a closed-chamber instrument 
for measurement of transepidermal water loss (TEWL) to estimate skin barrier function 
accurately [5]. We also applied a new method of measuring out-in skin transparency 
(OIST), using a colorimeter and food dye to evaluate skin barrier function [6]. Pruritus 
and satisfaction with therapy were also evaluated using the visual analogue scale (VAS). 
As other factors for objective evaluation, we performed bacterial skin cultures specific 
for Staphylococcus aureus and blood sampling to measure serum LDH, TARC, and 
eosinophil blood counts. 
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2. Materials and methods 
2.1 Patients and clinical study design 
 The study was approved by the Institutional Review Board at Chiba University 
(ID: 1082) and conducted in accordance with the Declaration of Helsinki. It was 
registered with the UMIN Clinical Trial Registry (ID: 6136, official title: “Effect of 
ultrapure soft water on skin function of atopic dermatitis”). The trial design was a 
randomized, double-blind, placebo-controlled, crossover pilot study. The CONSORT 
2010 flow diagram for this study and the study design are shown in Fig. 1. Eligibility 
criteria for the study were presence of mild to moderate AD in child patients between 3 
and 6 years of age. AD patients who were administered systemic steroids or 
immunosuppressive therapy or those who had an EASI score > 20, a malignant disorder, 
or severe infectious disease were excluded.  
 Participants were recruited via poster advertisement at the Department of 
Dermatology or Pediatrics and at clinics and hospitals in Chiba City. Eligibility for 
interested parents of patients for study participation was assessed in a telephone 
interview by a pediatrician of Chiba University Hospital. Diagnosis, clinical 
examinations for assessment of EASI, and measurement of skin barrier functions 
including TEWL and OIST were performed by a dermatologist of Chiba University 
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Hospital. Blood tests, including peripheral eosinophil counts and serum TARC and LDH 
levels, urine tests, and bacterial skin cultures were conducted at the Department of 
Pediatrics, Chiba University Hospital.  
 We performed bacterial cultures of Staphylococcus aureus sampled from skin 
on the forearm, chest, and back at each assessment visit according to a procedure 
described previously [7]. We used stamp-type Staphylococcus aureus-selective TGSE 
agar (Food Stamp
®
; Nissui Pharmaceutical Co., Ltd.) as the culture medium, and the 
cultures were incubated at 37˚C for 24 h under aerobic conditions. A positive culture 
was defined as the presence of more than one colony of Staphylococcus aureus on the 
agar. We picked the colonies and incubated them in Trypticase Soy II Agar with 5% 
Sheep Blood
®
 (Becton, Dickinson and Company Co., Ltd) at 37˚C for 24 h under 
aerobic conditions. We then identified Staphylococcus aureus based on the agglutination 
test. 
 Pruritus and therapy satisfaction were evaluated by the mother of the patient 
using the VAS. All patients and their parents provided informed consent. We informed 
the patients and their parents that this trial consisted of two cycles of 6-week UPSW 
treatments separated by a 2-week washout period using tap water. An employee of 
Miura Co., Ltd. (Matsuyama, Japan) directed the placement of the UPSW units in the 
9 
 
patients’ homes. Both the patients and research doctors were blinded to the treatment 
allocation throughout the study period. 
 Patients were randomly assigned to two treatment groups on a 1:1 basis by a 
third party via flipping a coin to allow randomization: 6-week shower treatment with 
UPSW versus with placebo groups. A machine used to supply either UPSW (Bihadakko; 
Miura Co., Ltd.) or ordinary tap water without cation-exchange resin (placebo) was set 
up in the bathroom of each home. The hardness of the UPSW was ≤ 1.0 mg/L in this 
study. After a 2-week washout period using tap water only, the treatment protocols were 
switched, and a second 6-week treatment was then performed. Shower treatment was 
not considered a special therapy, simply patients using UPSW once a day during their 
usual bathing routine. Each patient continued using their normal therapies and 
medications in the same doses or quantities as used before the study. The baseline and 
endpoint values of outcomes such as EASI, TEWL, and VAS scores for pruritus and 
satisfaction with therapy were compared.  
  
2.2 Sample size 
 In general, we calculate the number of subjects required to detect significance 
at a 5% significance level with 80% power. The original sample size estimate was 30 
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participants at the time of initial protocol registration. We determined the study period 
to be 1.5 years and recruited patients from October 2011 to March 2013, excluding the 
summer season of July and August to avoid excessive sweating, which is a potential 
bias. Finally, 12 patients (5 females) were entered into the study. Although this number 
was less than anticipated, we proceeded with the analysis of these patients as a pilot 
study.  
 
2.3 Interventions 
 The units equipped with a cation-exchange resin for obtaining UPSW, in which 
Ca
2+
 and Mg
2+
 have been almost completely replaced by sodium ions, were compared 
with the placebo unit, which had the same appearance but without the cation-exchange 
resin, thus releasing ordinary tap water. The subjects on their own could not distinguish 
whether the unit was the placebo or the UPSW unit. All units were installed in the child 
AD patient’s home and then replaced at the time of crossover by a Miura engineer. The 
engineer sampled the water upon both installing and removing the units. The hardness 
(≤ 1.0 mg/L) and quality of both the tap water and UPSW were monitored in the 
laboratory of Miura Co., Ltd.  
 Patients received UPSW shower treatment for the first 6 weeks (group 1) or 
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between weeks 9 and 15 (group 2) of the trial (Fig. 1). Basically, throughout the study 
period, the patients remained in their homes with the exception of going out during the 
day.    
 
2.4 Primary outcome 
 At the time of study registration, the five separate primary outcomes included 
the mean change in the EASI (as an evaluation of skin conditions), OIST and TEWL (as 
measures of skin barrier function), the VAS scores for pruritus, and serum TARC levels 
at 6 weeks compared with baseline. We also compared the mean changes in these five 
outcomes between the UPSW and placebo intervention groups. At the start of this trial, 
we added satisfaction with therapy as an additional outcome to evaluate the feelings 
experienced by the patients in regard to treatment effects. Serum TARC levels 
ultimately were excluded from among the primary outcomes and were evaluated as a 
secondary outcome, since we decided to perform blood tests only after treatment 
crossover to reduce the number of invasive tests.  
 The EASI score is measured on an objective severity scale ranging from 0 to 
72, and it was assessed by the same dermatologist at each follow-up appointment.  
 OIST is an assessment of out-in skin barrier function [6]. The penetration of 
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tartrazine (C16H9N4Na3O9S2, molecular weight 534: Wako Chemicals., Ltd., Osaka, 
Japan) was measured using the photocolorimeter model CR-400
®
 (Konica Minolta Co., 
Ltd., Tokyo, Japan). It can record colors in a three-dimensional space known as the CIE 
1976 L*a*b* color space based on the CIE XYZ coordinate system. We recorded b* 
values from an 11-mm diameter skin area of the forearm near the cubital fossa using the 
photocolorimeter to evaluate initial skin color. Fifty microliters of solution containing 
the hydrophilic yellow dye tartrazine dissolved in 10 mg/ml saline was applied to a 
small water-proofed cotton patch (5 × 5 mm). After 30 min, the patch was removed, the 
solution was flushed with soap, and the b* values were re-evaluated.  
 TEWL is an assessment for in-out skin barrier function, measured using the 
AquaFlux
®
 (Biox System, London, UK) condenser-chamber, which is reported to be 
approximately 40% more sensitive than an open chamber instrument [8]. TEWL values 
were measured along the same abdominal and upper back regions in each subject. All 
tests, including TEWL, were performed in the same room with a controlled temperature 
ranging from 24 to 26ºC and a humidity of 20 to 40%. Each measurement was obtained 
more than 1 h after the patient’s arrival at our hospital.  
 We also evaluated pruritus and satisfaction with therapy using the VAS, which 
is a symptom subjective severity scale ranging from 0 to 10 and was completed by the 
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parents of the patients at each assessment visit.  
 
2.5 Secondary outcome 
 At the time of initial protocol registration, the secondary outcomes included 
bacterial infection in skin, urine levels of allergy-related substances, and the amount of 
topical agents used. However, we failed to evaluate the amount of topical agents used as 
a secondary outcome, because we instructed each patient to maintain their same 
therapies and medications, including ointments, in the same doses or amount during the 
course of this clinical trial as used prior to the start of this study. We performed bacterial 
cultures for Staphylococcus aureus at each assessment visit in addition to urine tests. In 
addition to serum TARC levels, we evaluated peripheral eosinophil counts and serum 
LDH levels as blood sampling data. 
 
2.6 Statistical analysis 
 All data were analyzed according to the intention-to-treat principle. For the 
baseline characteristics, summary statistics were expressed as frequencies and 
proportions for categorical data and as means and standard deviations (SD) for 
continuous variables. We compared patient characteristics using Fisher’s exact test for 
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categorical outcomes and t-tests or the Wilcoxon rank sum test for continuous variables, 
as appropriate.   
 The mean changes from baseline were computed for all outcome variables. The 
mean changes were analyzed using a repeated-measures analysis of variance (ANOVA) 
based on the Grizzle model, including effects for treatment, period, and subject 
sequence as a random effect. A 2 × 2 crossover study design model was used to evaluate 
the carry-over or learning effect [9]. 
 All statistical analyses were performed using SAS software version 9.3 (SAS 
Institute, USA) and GraphPad Prism (version 6; GraphPad Software). All comparisons 
were planned, and the tests were two-sided. P < 0.05 was considered to indicate a 
statistically significant difference.  
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3. Results 
 A total of 12 patients were assigned randomly to two groups differing only in 
treatment protocol sequence (Table 1). Group 1 contained six patients (two female, 
mean age ± SD: 63.5 ± 5.7 months, EASI ± SD: 10.67 ± 5.35) and was started with a 
6-week UPSW shower treatment as the first allocation (water hardness: 91.67 ± 38.25 
mg/L), while group 2 contained six patients (three females, mean age ± SD: 52.0 ± 14.2 
months, EASI ± SD: 7.02 ± 5.15) and was started with a 6-week placebo shower 
treatment (water hardness: 72.5 ± 9.44 mg/L) (Fig. 1). After a 2-week washout period, 
the treatment protocols were switched between the two patient groups as the second 
allocation. One patient in group 1 withdrew her consent within the first 3 weeks for 
personal reasons, while the remaining 11 completed the entire course (Fig. 1). 
 In the statistical analysis using the Grizzle model for crossover design [9], there 
were no carry-over, period or sequence effects. There were no adverse events caused 
from using the installed water softening unit or the placebo unit. Therefore, we 
performed the following analysis to compare the UPSW versus placebo interventions 
and also to compare several factors pre-treatment (baseline) versus post-treatment 
(endpoint) within each treatment group. 
 With respect to clinical evaluation of the skin as a primary outcome, when 
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baseline and endpoint values were compared within the UPSW treatment group, the 
mean EASI showed a tendency to improve; however, this difference did not reach 
statistical significance (P = 0.077, Fig. 2A) same as the placebo treatment group which 
showed no tendency to improve (Fig. 2B) No significant differences were recognized in 
the mean changes in the EASI between the UPSW and placebo treatments (Fig. 2C).  
 In terms of skin barrier function, the mean changes in OIST from baseline to 
endpoint within the UPSW treatment group showed no significant differences (P = 
0.120, Fig. 3A) same as the placebo treatment group (Fig. 3B). On the other hand, the 
mean change in OIST was significantly greater in the UPSW than the placebo treatment 
group (P = 0.048, Fig. 3C). 
 In contrast, the TEWL in skin from both the abdominal (Fig. 4) and upper back 
(Fig. 5) regions showed no significant differences between the two water treatments or 
from baseline to endpoint within the UPSW treatment group. 
 In the evaluation of subjective symptoms using the VAS, the mean VAS scores 
for pruritus showed no significant differences from baseline to endpoint within the each 
water treatment group (Fig. 6A, B). However, there was statistically significant 
difference between the two water treatments in terms of the mean VAS scores for both 
pruritus (P = 0.044, Fig. 6C). The mean VAS scores for satisfaction with therapy also 
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showed a significant improvement from baseline to endpoint in the UPSW treatment 
group (P = 0.010, Fig. 7A), while it did not show improvement in the placebo treatment 
group (Fig. 7B). In terms of the VAS scores for satisfaction with therapy, there was 
statistically significant difference between the two water treatments (P = 0.022, Fig. 
7C). 
 Table 2 summarizes the results shown in Figs. 2-7. There were statistically 
significant differences between the UPSW and placebo treatments with respect to the 
following three independent primary outcomes (OIST and VAS scores for pruritus and 
satisfaction with therapy). In addition, we detected a significant improvement in the 
VAS scores for satisfaction with therapy within the UPSW treatment period. 
 We also show a summary of the following secondary outcomes in Table 3: 
Staphylococcus aureus cultures in skin from the three body parts evaluated (Figs. 8-10), 
serum TARC (Fig. 11) and LDH levels (Fig. 12), and peripheral eosinophil counts (Fig. 
13). However, these data indicated no significant improvements with UPSW treatment.  
 We counted Staphylococcus aureus colonies among the bacterial cultures 
sampled from the right forearm (Fig. 8), back (Fig. 9), and chest (Fig. 10), but there 
were no significant changes in the number of colonies. The only significant increase 
was detected in the right forearm during the tap water treatment period (Fig. 8B). 
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 As for the laboratory findings assessed, we could not collect adequate urine 
data, because some patients were not willing to urinate at the time of assessment. No 
significant differences in serum TARC (Fig. 11) or LDH levels (Fig. 12) or in peripheral 
eosinophil counts (Fig. 13) were detected from baseline to endpoint within the UPSW 
treatment period or between the two treatment groups.  
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4. Discussion 
4.1 Main findings 
 In this study, we measured disease severity, which was evaluated by the EASI, 
as one of the primary outcomes. Other trials investigating water softeners for children 
with moderate to severe eczema showed no significant improvements in disease severity 
[10, 11]. However, they discussed the possibility that water softening is beneficial for 
milder forms of eczema. Therefore, in this study we excluded patients with an EASI 
score > 20. Even though UPSW treatment for 6 weeks had a tendency to improve the 
EASI in children with mild AD, we could not detect a significant difference between the 
two water treatments. This study was relatively short in duration and potentially 
insufficient to evaluate the effects of UPSW treatment, and significant improvements 
might have been detected if the observation period had been increased. 
 On the other hand, we succeeded in showing that a 6-week shower treatment 
with UPSW significantly improved OIST, as another independent primary outcome, in 
child AD patients compared with tap water.  
 Mochizuki et al. previously showed a significant increase in OIST in patients 
with AD, which was not found in patients with dry skin or in control subjects, and they 
proved the efficacy of using OIST for evaluation of out-in skin barrier function [6]. 
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OIST is a direct measurement of tartrazine (molecular weight 534) penetration into the 
skin, and it may correlate with the large spaces existing between epidermal cells and 
with barrier dysfunction due to both water loss and nonspecific irritants. On the other 
hand, TEWL is an indicator only of in-out barrier function and the diffusion of 
evaporated water molecules through the stratum corneum [12]. In general, small 
children with high activity levels are prone to sweating, which easily influences the 
value of TEWL [13]. Our data also suggest that OIST is more accurate than TEWL for 
evaluation of skin barrier function in children.  
 We also found statistical significance for subjective symptoms evaluated by the 
VAS, such as improvement in pruritus and satisfaction with therapy, with the UPSW 
treatment. These results were supported by the efficacy of UPSW in a previous study in 
NC/Nga mice, a murine model for AD, and in dogs with pruritus [14].  
 Previous studies have shown that low extracellular concentrations of Ca
2+
 and 
Mg
2+
 in the epidermis accelerated skin barrier repair, whereas an increase in the 
concentration of NaCl did not disturb the recovery of disrupted skin barriers [15, 6]. It 
was also demonstrated that a low extracellular concentration of Ca
2+
 in the epidermis 
led to exocytosis of lamellar bodies required for skin barrier function [17]. In general, 
Ca
2+
 and Mg
2+
 react with soap to form an insoluble precipitate known as “soap scum” 
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that binds tightly to the skin surface and cannot be rinsed away easily; we speculate that 
soap scum may exacerbate AD, based on the results of our previous and this study [14].
 The lesional skin of more than 90% of patients with AD is colonized by 
Staphylococcus aureus, which exacerbates AD, whereas most healthy individuals do not 
harbor the pathogen [18]. Staphylococcal δ-toxin may promote allergic immune 
responses [19]. Therefore, we also obtained Staphylococcus aureus cultures from the 
skin surface of the forearm, back, and chest. However, we failed to detect any 
significant differences in the number of colonies between the two different water 
treatments and during each treatment period, excluding the significant increase in the 
forearm during the tap water treatment period.  
 
4.2 Limitations   
 This was a pilot study with only a small number of subjects; however, it was a 
randomized, double-blind, placebo-controlled, crossover design. The study cost per 
patient to set up the UPSW machine in each home and to continuously monitor the 
quality of UPSW prevented us from recruiting a large number of patients. It was also 
possible that the effects were masked by typical eczema therapy, generally topical 
steroids, despite the restriction to maintain the same therapies and medications during 
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the trial as used prior to its start. The start time of the study could also have created bias; 
for example, the rainy summer season before the dry fall and winter seasons.  
 We found no significant differences between the two groups with regard to 
serum TARC (Fig. 11) and LDH levels (Fig. 12) and peripheral eosinophil counts (Fig. 
13). Because of the young age of the patients, we took only a small number of blood 
samples from each patient after the crossover. 
 
4.3 Generalizability 
 This trial had adequate external validity, since the child AD participants were 
recruited from the general public and not from a special environment. Indeed, the rate of 
parents involved who continued to use the UPSW unit after the end of this trial reached 
80%, which reflected the high improvement rate of pruritus and satisfaction with 
therapy. Moreover, the satisfaction of the patients who underwent UPSW shower 
treatment during the trial period was also high. We believe the results are applicable to 
not only child AD patients but that UPSW is also beneficial for adults with mild to 
moderate eczema or with dry skin alone. It is possible that UPSW is more beneficial for 
European than Japanese AD patients, because the water hardness of home tap water is 
generally much higher in Europe.  
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4.4 Interpretation  
 To our knowledge, this is the first study to investigate the direct effects of 
UPSW on skin barrier function in child AD patients as a randomized, double-blind, 
placebo-controlled, crossover study. We also found improvement in pruritus and 
satisfaction with therapy. It was notable that we could obtain these results in Japan 
where water hardness is much lower than in European countries. Long-term studies 
involving larger sample numbers over a wide age group will help confirm the efficacy 
of this UPSW shower treatment in mild to moderate adult AD patients in addition to 
child AD patients.  
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Figure legends 
Fig. 1. CONSORT 2010 flow diagram and study design of the clinical trial evaluating 
shower treatment with UPSW.  
Details are described in Materials and methods. UPSW: ultra-pure soft water, EASI: 
eczema area and severity index, VAS: visual analogue scale, TEWL: transepidermal 
water loss, OIST: out-in skin transparency 
 
Fig. 2. UPSW did not improve the EASI.  
A-B, EASI scores were plotted pre-treatment (baseline) and post-treatment (endpoint) 
from the first and last allocations. C, the mean changes in the EASI between the UPSW 
and placebo (tap water) were plotted. None of the data showed significant differences, 
although the EASI scores within the UPSW treatment period showed a tendency for 
improvement (A, P = 0.077). These data were analyzed using repeated-measures 
analysis of variance based on the Grizzle model. UPSW: ultra-pure soft water, EASI: 
eczema area and severity index, n.s.: not significant. 
 
Fig. 3. OIST was significantly lower in the UPSW group than the placebo group. 
A, B, OIST was plotted pre-treatment (baseline) and post-treatment (endpoint) from the 
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first and last allocations. C, the mean changes in OIST between the UPSW and placebo 
were plotted. The change was significantly lower in the latter. (P = 0.048). These data 
were analyzed using repeated-measures analysis of variance based on the Grizzle model. 
UPSW: ultra-pure soft water, OIST: out-in skin transparency, n.s.: not significant. 
 
Fig. 4. UPSW did not improve TEWL in the abdominal region. 
A, B, TEWL was plotted pre-treatment (baseline) and post-treatment (endpoint) from the 
first and last allocations. C, The mean differences in TEWL between the UPSW and 
placebo (tap water) were plotted. None of the data showed significant differences. The 
mean TEWL in the UPSW group, however, showed a tendency to improve (A, P = 
0.096). These data were analyzed using repeated-measures analysis of variance based 
on the Grizzle model. UPSW: ultra-pure soft water, TEWL: transepidermal water loss, 
n.s.: not significant. 
 
Fig. 5. UPSW did not improve TEWL in the upper back region. 
A, B, TEWL was plotted at pre-treatment (baseline) and post-treatment (endpoint) from 
the first and last allocations. C, The mean changes in TEWL between the UPSW and 
placebo (tap water) were plotted. None of the data showed significant differences. These 
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data were analyzed using repeated-measures analysis of variance based on the Grizzle 
model. UPSW: ultra-pure soft water, TEWL: transepidermal water loss, n.s.: not 
significant. 
 
Fig 6. The VAS scores for pruritus were significantly lower in the UPSW group than the 
placebo group. 
A, B, The VAS scores for pruritus were plotted at pre-treatment (baseline) and 
post-treatment (endpoint) from the first and last allocations. The VAS scores in the 
UPSW group showed a tendency to improve (A, P = 0.087). C, the mean changes in the 
VAS scores for pruritus between the UPSW and placebo treatments (tap water) were 
plotted, and the VAS score was significantly lower in the UPSW group than the placebo 
group (*P = 0.044). These data were analyzed using repeated-measures analysis of 
variance based on the Grizzle model. UPSW: ultra-pure soft water, VAS: visual 
analogue scale, n.s: not significant. 
 
Fig 7. UPSW improved the VAS score for satisfaction with therapy. 
A, B, The VAS scores for satisfaction with therapy were plotted at pre-treatment 
(baseline) and post-treatment (endpoint) from the first and last allocations. The VAS 
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scores in the UPSW group improved significantly (A, *P = 0.010). C, The mean 
changes in the VAS scores between the UPSW and placebo treatments (tap water) were 
plotted, and the score was significantly lower in the UPSW than placebo group (*P = 
0.022). These data were analyzed using repeated-measures analysis of variance based 
on the Grizzle model. UPSW: ultra-pure soft water, VAS: visual analogue scale, n.s: not 
significant. 
 
Fig 8. The colony counts of Staphylococcus aureus on skin from the right forearm did 
not decrease after UPSW therapy. 
A, B, The colony counts of Staphylococcus aureus on the skin of the right forearm were 
plotted at pre-treatment (baseline) and post-treatment (endpoint) from the first and last 
allocations. Colony forming units (CFU) were significantly higher in the placebo (tap 
water)- than the UPSW-allocated patients (B, *P = 0.035). C, The mean changes in CFU 
between the UPSW and placebo (tap water) treatments were plotted. No significant 
differences were detected in these data, according to the Wilcoxon signed-rank test for 
matched pairs.  
 
Fig 9. The colony counts of Staphylococcus aureus on skin from the chest region did 
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not decrease after UPSW therapy. 
A, B, The colony counts of Staphylococcus aureus on skin from the chest were plotted 
at pre-treatment (baseline) and post-treatment (endpoint) from the first and last 
allocations. C, The mean changes in CFU between the UPSW and placebo (tap water) 
treatments were plotted. No significant differences were detected in these data, 
according to the Wilcoxon signed-rank test for matched pairs.  
 
Fig 10. The colony counts of Staphylococcus aureus on skin from the back did not 
decrease after UPSW therapy. 
A, B, The colony counts of Staphylococcus aureus on skin from the back were plotted 
at pre-treatment (baseline) and post-treatment (endpoint) from the first and last 
allocations. C, The mean changes in CFU treatments were plotted. No significant 
differences were detected in these data, according to the Wilcoxon signed-rank test for 
matched pairs.  
 
Fig 11. Serum TARC levels did not decrease after UPSW therapy. 
A, B, Serum TARC levels were plotted at pre-treatment (baseline) and post-treatment 
(endpoint) from the first and last allocations. C, The mean changes in serum TARC 
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levels between the UPSW and placebo (tap water) treatments were plotted. None of the 
data showed significant differences. TARC: thymus and activation-regulated chemokine. 
These data were analyzed using the Wilcoxon signed-rank test for matched pairs (A, B) 
and Mann Whitney test (C). 
 
Fig 12. Serum LDH levels did not decrease after UPSW therapy. 
A, B, Serum LDH levels were plotted at pre-treatment (baseline) and post-treatment 
(endpoint) from the first and last allocations. C, The mean change in serum LDH levels 
between the UPSW and placebo (tap water) treatments were plotted. None of the data 
showed significant differences. LDH: lactate dehydrogenase. These data were analyzed 
using the Wilcoxon signed-rank test for matched pairs (A, B) and Mann Whitney test 
(C). 
 
Fig 13. Peripheral eosinophil counts did not decrease after UPSW therapy. 
A, B, Peripheral eosinophil counts were plotted at pre-treatment (baseline) and 
post-treatment (endpoint) from the first and last allocations. C, The mean changes in 
peripheral eosinophil counts levels between the UPSW and placebo (tap water) 
treatments were plotted. None of the data showed significant differences. These data 
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were analyzed using the Wilcoxon signed-rank test for matched-pairs (A, B) and Mann 
Whitney test (C). 
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Table 1.  Baseline characteristics of the patients. 
 
UPSW: ultra-pure soft water, EASI: eczema area and severity index score 
  
Characteristics Group 1 
(UPSW/ Tap water) 
Group 2 
(Tap water/ UPSW) 
Number of enrolled patients 
(male: female) 
6 (4:2) 6 (3:3) 
Mean age ± SD, months 63.5 ± 5.7 52.0 ± 14.2 
Water hardness in tap water ± SD, 
mg/L  
91.67 ± 38.25 72.5 ± 9.44 
Baseline EASI scores ± SD 10.67 ± 5.35 7.02 ± 5.15 
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Table 2.  Baseline, endpoint and change values of the primary outcomes. 
Outcomes UPSW Tap water (placebo) 
p-value
2
 
LS mean 95% CI p-value
1
 LS mean 95% CI p-value
1
 
EASI Baseline 9.15 5.31 – 12.9 
0.077 
6.55 3.78 – 9.32 
0.92 
 
Endpoint 6.68 3.72 – 9.64 6.40 3.45 – 9.36  
Change -2.70 -5.77 – 0.35  -0.098 -3.16 – 2.96  0.21 
OIST (b* values) Baseline 6.62 3.29 – 9.94 
0.120 
4.38 3.17 – 5.58 
0.94 
 
Endpoint 4.33 2.49 – 6.17 4.43 2.77 – 6.08  
Change -2.42 -4.81 – 0.038  0.055 -2.33 – 2.44   0.048* 
TEWL (abdominal 
region, g/m
2
h) 
Baseline 33.1 13.3 – 52.8 
0.096 
26.8 11.6 – 41.8 
0.92 
 
Endpoint 27.5 8.49 – 46.4 26.5 9.99 – 43.1  
Change -5.81 -12.0 – 0.43  -0.037 -6.28 – 6.21  0.14 
TEWL (upper back 
region, g/m
2
h) 
Baseline 31.2 10.9 – 51.3 
0.60 
32.9 12.2 – 53.5 
0.54 
 
Endpoint 29.2 9.29 – 49.1 28.4 12.3 – 44.4  
Change -2.36 -15.8 – 11.1  -4.62 -18.1 – 8.89  0.79 
VAS (pruritus) Baseline 5.19 3.87 – 6.50 
0.087 
3.61 1.88 – 5.34 
0.21 
 
Endpoint 3.61 1.85 – 5.38 4.19 2.31 – 6.06  
Change -1.53 -3.10 – 0.037  0.56 -1.00 – 2.13   0.044* 
VAS (satisfaction 
with therapy) 
Baseline 4.78 3.35 – 6.21 
 0.010* 
6.34 4.51 – 8.17 
0.69 
 
Endpoint 6.50 4.80 – 8.19 6.42 4.55 – 8.29  
Change 1.74 0.78 – 2.71  0.098 -0.86 – 1.06   0.022* 
 
CI: confidence interval, LS mean: least-squares mean, UPSW: ultra-pure soft water, EASI: eczema 
area and severity index score, VAS: visual analogue scale, TEWL: transepidermal water loss, OIST: 
out-in skin transparency. 
p-value
1
: change from baseline to endpoint, p-value
2 
: between-treatment comparison of the mean 
change.  
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Table 3.  Baseline, endpoint and change values of the secondary outcomes. 
 
 
CI: confidence interval, LS mean: least-squares mean, UPSW: ultra-pure soft water, 
TARC: thymus and activation-regulated chemokine, LDH: lactate dehydrogenase,  
p-value
1
: change from baseline to endpoint, p-value
2
: between-treatment comparison of the mean 
change. 
 
 
 
  
Outcomes UPSW Tap water (placebo) 
p-value
2
 
LS mean 95% CI p-value
1
 LS mean 95% CI p-value
1
 
Cultures of 
Staphylococcus aureus  
(right forearm, CFU) 
Baseline 16.50 5.291 – 39.71 
0.523 1.000 -3.977 – 30.16 0.035*   
Endpoint 2.500 1.324 – 29.48 14.00 4.843 – 36.61   
Change -2.500 -29.14 – 14.94   5.000 -0.7020 – 15.97   0.125 
Cultures of 
Staphylococcus aureus  
(chest, CFU) 
Baseline 33.00 12.78 – 49.22 
0.193 2.000 -7.209 – 38.12 0.555   
Endpoint 52.50 19.38 – 67.42 6.000 5.873 – 43.40   
Change 5.00 -8.416 – 33.22   0.0 -14.21 – 32.57    0.77 
Cultures of 
Staphylococcus aureus  
(back, CFU) 
Baseline 36.00 20.05 – 63.35 
0.883 5.00 6.294 – 54.07 0.727   
Endpoint 41.50 22.28 – 59.72 3.00 2.592– 47.23   
Change 3.00 -17.78 – 16.38   0.0 -35.50 – 24.96   0.844 
Serum TARC 
(pg/ml) 
Baseline 2375 1660 – 3773 
0.445 1044 461.3 – 2105 0.625   
Endpoint 1795 1582 – 3279 1096 507.0 – 2051   
Change -48.50 -1222 – 649.9   -52.0 -521.3 – 513;7   0.90 
Serum LDH 
(U/L) 
Baseline 
302.5 261.5 – 352.0 
0.313 277.0 253.5 – 304.1 0.75   
Endpoint 321.5 269.8 – 388.8 278.0 241.5 – 314.9   
Change 21.50 -34.5– 79.71   -13.0 -22.26 – 21.06    0.563 
Peripheral eosinophil  
counts 
(/μl) 
Baseline 585.0 163.8 – 1046 
0.563 330.0 164.7 – 203.2 0.813   
Endpoint 465.0 65.26 – 1058 522.0 695.7 – 1029   
Change -38.0 0.78 – 2.71  -22.0 -420.1 – 791.7    0.649 
37 
 
 
Fig. 1. CONSORT 2010 flow diagram and study design for the clinical trial evaluating 
shower treatment with UPSW.  
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Fig. 2. UPSW did not improve the EASI. 
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Fig. 3. OIST was significantly lower in the UPSW group than placebo group. 
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Fig. 4. UPSW did not improve TEWL in skin from the abdominal region. 
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Fig. 5. UPSW did not improve TEWL in skin from the upper back region. 
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Fig. 6. The VAS scores for pruritus were significantly lower in the UPSW group than the 
placebo group. 
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Fig. 7. UPSW improved the VAS scores for satisfaction with therapy. 
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Fig 8. The colony counts of Staphylococcus aureus on skin from the right forearm did 
not decrease after UPSW therapy. 
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Fig. 9. The colony counts of Staphylococcus aureus on skin from the chest did not 
decrease after UPSW therapy. 
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Fig. 10. The colony counts of Staphylococcus aureus on skin from the back did not 
decrease after UPSW therapy. 
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Fig. 11. Serum TARC levels did not decrease after UPSW therapy. 
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Fig.12. Serum LDH levels did not decrease after UPSW therapy. 
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Fig. 13. Peripheral eosinophil counts did not decrease after UPSW therapy.  
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